AG

Adjucor Gmbh

www.adjucor.com link_icon

AdjuCor Company Research Report



Company Overview



  • Name: AdjuCor GmbH

  • Mission: AdjuCor is dedicated to improving the lives of patients with advanced heart failure through pioneering revolutionary treatments.

  • Founded: No information is available.

  • Founder(s): No information is available.

  • Key People:

  • Prof. Dr. med. Stephen Wildhirt - Chief Executive and Medical Officer, Co-Founder

  • Dr. Andreas Maier - Chief Technology and Production Officer

  • Dr. Johannes Clauss - Chief Operations and Technology Officer

  • Dr. Hamman de Vaal - Senior Commercial and Clinical Advisor

  • Headquarters: 18 Neumarkter Street, 81673 Munich, Germany

  • Number of Employees: Over 40 staff members across development, manufacturing, clinical, and support roles.

  • Revenue: No information is available.

  • Known For: AdjuCor is known for its innovative approach in the treatment of advanced heart failure through the development of their minimally invasive device, reBEAT.


Products



reBEAT



  • Description: reBEAT is a minimally invasive, biventricular cardiac support device that provides mechanical circulatory support to assist one or both ventricles of a failing heart without blood contact.

  • Key Features:

  • Revolutionary Design: Avoids blood contact, minimizing risks of stroke and bleeding.

  • Minimally Invasive: Implantation involves a faster recovery, aiming for shorter hospital stays.

  • Tailored Needs: Provides pulsatile support and can be individually adjusted for patient-specific requirements.

  • Improved Quality of Life: Reduces complications and helps regain activities previously enjoyed.

  • Cost-effective: Shorter procedure times and reduced hospitalization costs.


Recent Developments



  • First-In-Human Implantations: In 2023, AdjuCor completed the world's first in-human implantation of the reBEAT device during a clinical feasibility trial, demonstrating its safety and effectiveness.

  • EU Co-Funded Project Launch: In January 2023, AdjuCor initiated a project co-funded by the EU to accelerate the market entry of the reBEAT device.

  • Funding Achievements:

  • June 2022: Awarded a €2.5 million EIC Accelerator grant from the European Innovation Council.

  • June 2021: Raised €29 million in a Series B funding round.

  • Collaborations and Support: AdjuCor enters research collaborations supported by the German federal and Bavarian provincial governments, and receives grants from the European Union.


Recent Publications and Presentations



  • Articles in journals such as JTCVS (April 2022) and Mater Sci Eng C (June 2019).

  • Presentation of preclinical results at major medical meetings like AATS 2021 and ISHLT 2021.


The company continues striving toward innovations in heart failure treatment, engaging in multidisciplinary collaborations and continuous clinical research endeavors.



Note: Some information fields were marked as not available due to lack of provided data.